These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24410846)

  • 1. How many people inject insulin? UK estimates from 1991 to 2010.
    Holden SE; Gale EA; Jenkins-Jones S; Currie CJ
    Diabetes Obes Metab; 2014 Jun; 16(6):553-9. PubMed ID: 24410846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and costs of diabetes treated with insulin in France.
    Detournay B; Raccah D; Cadilhac M; Eschwège E
    Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
    Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of managing severe hypoglycaemia in three European countries.
    Hammer M; Lammert M; Mejías SM; Kern W; Frier BM
    J Med Econ; 2009; 12(4):281-90. PubMed ID: 20001570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005.
    González EL; Johansson S; Wallander MA; Rodríguez LA
    J Epidemiol Community Health; 2009 Apr; 63(4):332-6. PubMed ID: 19240084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How many and who are receiving medication for diabetes mellitus?].
    Strøm H; Engeland A; Eriksen E; Sakshaug S; Rønning M
    Tidsskr Nor Laegeforen; 2006 Mar; 126(6):768-70. PubMed ID: 16541171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia, analogue insulins; prescribing cost or quality of life?
    Hitman GA
    Diabet Med; 2012 Mar; 29(3):289. PubMed ID: 22364579
    [No Abstract]   [Full Text] [Related]  

  • 8. Technology and the issue of cost/benefit in diabetes.
    Giannini C; Mohn A; Chiarelli F
    Diabetes Metab Res Rev; 2009 Sep; 25 Suppl 1():S34-44. PubMed ID: 19662616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
    Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
    Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of an increasing prevalence of diagnosed diabetes mellitus in the Poole area from 1983 to 1996.
    Gatling W; Budd S; Walters D; Mullee MA; Goddard JR; Hill RD
    Diabet Med; 1998 Dec; 15(12):1015-21. PubMed ID: 9868974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliably assessing the cost-effectiveness of continuous subcutaneous insulin infusion vs. multiple daily injections in the UK: what are the issues?
    Currie CJ
    Diabet Med; 2007 Oct; 24(10):1058-9. PubMed ID: 17888127
    [No Abstract]   [Full Text] [Related]  

  • 13. Trends in the use and cost of human and analogue insulins in a Colombian population, 2011-2015.
    Torres DR; Portilla A; Machado-Duque ME; Machado-Alba JE
    Public Health; 2017 Dec; 153():64-69. PubMed ID: 28950114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost of diabetes mellitus in Spain].
    González P; Faure E; Del Castillo A;
    Med Clin (Barc); 2006 Nov; 127(20):776-84. PubMed ID: 17198665
    [No Abstract]   [Full Text] [Related]  

  • 15. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.
    Currie CJ; Peters JR; Evans M
    Diabet Med; 2010 Jul; 27(7):744-52. PubMed ID: 20636954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries.
    Neubert A; Hsia Y; de Jong-van den Berg LT; Janhsen K; Glaeske G; Furu K; Kieler H; Nørgaard M; Clavenna A; Wong IC
    Br J Clin Pharmacol; 2011 Dec; 72(6):969-77. PubMed ID: 21689139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
    Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
    Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the future.
    Tucker DM; Palmer AJ
    Prim Care Diabetes; 2011 Apr; 5(1):9-17. PubMed ID: 21071296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.
    Hall GC; McMahon AD; Carroll D; Home PD
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):305-13. PubMed ID: 22271442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.